よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (50 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
65. 国立感染症研究所 カルバペネム耐性腸内細菌目細菌（carbapenem-resistant
Enterobacterales: CRE）病原体サーベイランス, 2022 年 IASR Vol. 45 p129-130: 2024
年 7 月号. 2024. at https://www.niid.go.jp/niid/ja/cre-m/cre-iasrd/12784-533d02.html )
4
5
6
66. Kayama S, et al. National genomic surveillance integrating standardized quantitative
susceptibility testing clarifies antimicrobial resistance in Enterobacterales. Nat Commun.
2023. 14(1):8046.
7
8
67. Oka K, et al. Clinical characteristics and treatment outcomes of carbapenem-resistant
Enterobacterales infections in Japan. J Glob Antimicrob Resist. 2022. 29:247-252.
9
10
11
68. Paniagua-García M, et al. Attributable mortality of infections caused by carbapenemresistant Enterobacterales: results from a prospective, multinational case-control-control
matched cohorts study (EURECA). Clin Microbiol Infect. 2024. 30(2):223-230.
12
13
14
15
69. Hayakawa K, et al. Comparison between IMP carbapenemase-producing
Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a
multicentre prospective study of the clinical and molecular epidemiology of carbapenemresistant Enterobacteriaceae. J Antimicrob Chemother. 2020. 75(3):697-708.
16
17
18
19
70. Saito S, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes
and Risk Factors of Patients with IMP-Type Carbapenemase-Producing CarbapenemResistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021.
65(3):e01483-20.
20
21
22
71. van Duin D, et al. Molecular and clinical epidemiology of carbapenem-resistant
Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect
Dis. 2020. 20(6):731-741.
23
72. 西村翔. 混同しがちな CRE と CPE のハナシ(2). J-IDEO. 2019. 3(3):346-55.
24
25
26
73. Yano H, et al. High frequency of IMP-6 among clinical isolates of metallo-β-lactamaseproducing Escherichia coli in Japan. Antimicrob Agents Chemother. 2012. 56(8):45544555.
27
28
29
74. EUCAST guidelines for the detection of resistance mechanisms and specific resistances
of clinical and/or epidemiological importance, v2. 2017. at
https://www.eucast.org/resistance_mechanisms.)
30
31
32
75. Chen Y, et al. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of
Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review
and Meta-Analysis. Microbiol Spectr. 2022. 10(2):e0260321.
33
34
35
76. Falcone M, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Clin Infect Dis. 2021. 72(11):1871-1878.
36
37
38
77. Lima O, et al. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48
carbapenemase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2022.
41(9):1173-1182.
39
78. 西村翔. CRE の治療(4). J-IDEO. 2020. 4(4):99-105.
40
41
79. Perez F, et al. Polymyxins: To Combine or Not to Combine? Antibiotics (Basel). 2019.
8(2):38.
42
43
44
80. Suzuki D, et al. Clinical and genomic characteristics of IMP-producing Enterobacter
cloacae complex and Klebsiella pneumoniae. Antimicrob Agents Chemother.
68(5):e0167223.
50
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
65. 国立感染症研究所 カルバペネム耐性腸内細菌目細菌（carbapenem-resistant
Enterobacterales: CRE）病原体サーベイランス, 2022 年 IASR Vol. 45 p129-130: 2024
年 7 月号. 2024. at https://www.niid.go.jp/niid/ja/cre-m/cre-iasrd/12784-533d02.html )
4
5
6
66. Kayama S, et al. National genomic surveillance integrating standardized quantitative
susceptibility testing clarifies antimicrobial resistance in Enterobacterales. Nat Commun.
2023. 14(1):8046.
7
8
67. Oka K, et al. Clinical characteristics and treatment outcomes of carbapenem-resistant
Enterobacterales infections in Japan. J Glob Antimicrob Resist. 2022. 29:247-252.
9
10
11
68. Paniagua-García M, et al. Attributable mortality of infections caused by carbapenemresistant Enterobacterales: results from a prospective, multinational case-control-control
matched cohorts study (EURECA). Clin Microbiol Infect. 2024. 30(2):223-230.
12
13
14
15
69. Hayakawa K, et al. Comparison between IMP carbapenemase-producing
Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a
multicentre prospective study of the clinical and molecular epidemiology of carbapenemresistant Enterobacteriaceae. J Antimicrob Chemother. 2020. 75(3):697-708.
16
17
18
19
70. Saito S, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes
and Risk Factors of Patients with IMP-Type Carbapenemase-Producing CarbapenemResistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021.
65(3):e01483-20.
20
21
22
71. van Duin D, et al. Molecular and clinical epidemiology of carbapenem-resistant
Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect
Dis. 2020. 20(6):731-741.
23
72. 西村翔. 混同しがちな CRE と CPE のハナシ(2). J-IDEO. 2019. 3(3):346-55.
24
25
26
73. Yano H, et al. High frequency of IMP-6 among clinical isolates of metallo-β-lactamaseproducing Escherichia coli in Japan. Antimicrob Agents Chemother. 2012. 56(8):45544555.
27
28
29
74. EUCAST guidelines for the detection of resistance mechanisms and specific resistances
of clinical and/or epidemiological importance, v2. 2017. at
https://www.eucast.org/resistance_mechanisms.)
30
31
32
75. Chen Y, et al. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of
Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review
and Meta-Analysis. Microbiol Spectr. 2022. 10(2):e0260321.
33
34
35
76. Falcone M, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Clin Infect Dis. 2021. 72(11):1871-1878.
36
37
38
77. Lima O, et al. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48
carbapenemase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2022.
41(9):1173-1182.
39
78. 西村翔. CRE の治療(4). J-IDEO. 2020. 4(4):99-105.
40
41
79. Perez F, et al. Polymyxins: To Combine or Not to Combine? Antibiotics (Basel). 2019.
8(2):38.
42
43
44
80. Suzuki D, et al. Clinical and genomic characteristics of IMP-producing Enterobacter
cloacae complex and Klebsiella pneumoniae. Antimicrob Agents Chemother.
68(5):e0167223.
50